Research Highlights on Atopic Dermatitis: Practice-Changing Results From Recent Clinical Trials*

Download All
From the 2020 Annual Meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Dermatology (AAD), and Revolutionizing Atopic Dermatitis (RAD).
Review the latest AD management data with Capsule Summaries and gain expert insights from brief commentaries and an on-demand Webcast covering key studies from the 2020 AAAAI, AAD, and RAD conferences.
person default
Andrew F. Alexis, MD, MPH
Jonathan Silverberg, MD

Highlights on Atopic Dermatitis

Slidesets BREEZE-AD5 Study Results: Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis
Slidesets Efficacy and Safety of Treatment Withdrawal and Retreatment With Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
Slidesets Pooled Data From BREEZE-AD1 and BREEZE-AD2 Examining the Efficacy and Safety of Baricitinib in Patients With Atopic Dermatitis and Atopic Comorbidities
Slidesets Dupilumab for Erythrodermic AD: Results From a Pooled Subgroup Analysis
Slidesets LIBERTY AD PEDS Study Results: Efficacy and Safety of Dupilumab in Children Aged ≥ 6 to < 12 Yrs With Severe Atopic Dermatitis
Slidesets JADE MONO-2 Study Results: Efficacy and Safety of Abrocitinib in Patients With Moderate to Severe Atopic Dermatitis

Following the virtual 2020 American Academy of Dermatology and Revolutionizing Atopic Dermatitis conferences, I describe several of the most clinically relevant data on approved and investigational treatments that have the potential to improve outcomes for our patients.

person default Andrew F. Alexis, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Released: August 10, 2020 Expired: August 9, 2021

With selective JAK inhibitors currently under investigation for AD, we could see greater efficacy without the safety tradeoffs of broad JAK inhibition.

Jonathan Silverberg, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Released: August 12, 2020 Expired: August 11, 2021
Provided by Clinical Care Options.
Contact Info

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This educational activity is supported by educational grants from
AbbVie Inc.
Pfizer Inc.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?